Does PEGASPARGASE Cause Hepatic steatosis? 152 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 152 reports of Hepatic steatosis have been filed in association with PEGASPARGASE (ONCASPAR). This represents 1.3% of all adverse event reports for PEGASPARGASE.
152
Reports of Hepatic steatosis with PEGASPARGASE
1.3%
of all PEGASPARGASE reports
20
Deaths
90
Hospitalizations
How Dangerous Is Hepatic steatosis From PEGASPARGASE?
Of the 152 reports, 20 (13.2%) resulted in death, 90 (59.2%) required hospitalization, and 16 (10.5%) were considered life-threatening.
Is Hepatic steatosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEGASPARGASE. However, 152 reports have been filed with the FAERS database.
What Other Side Effects Does PEGASPARGASE Cause?
Febrile neutropenia (1,589)
Pyrexia (706)
Febrile bone marrow aplasia (668)
Sepsis (548)
Vomiting (530)
Neutropenia (521)
Abdominal pain (469)
Hypertriglyceridaemia (399)
Hypotension (388)
Thrombocytopenia (382)
What Other Drugs Cause Hepatic steatosis?
METHOTREXATE (1,400)
ADALIMUMAB (1,058)
ETANERCEPT (620)
TOCILIZUMAB (476)
TOFACITINIB (405)
LEFLUNOMIDE (359)
HYDROXYCHLOROQUINE (358)
ABATACEPT (345)
METFORMIN (343)
INFLIXIMAB (325)
Which PEGASPARGASE Alternatives Have Lower Hepatic steatosis Risk?
PEGASPARGASE vs PEGASYS
PEGASPARGASE vs PEGCETACOPLAN
PEGASPARGASE vs PEGFILGRASTIM
PEGASPARGASE vs PEGFILGRASTIM-APGF
PEGASPARGASE vs PEGFILGRASTIM-BMEZ